• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎相关毛霉菌病、糖尿病与类固醇治疗:墨西哥西部单一中心的经验

COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico.

作者信息

Guzmán-Castro Salvador, Chora-Hernandez Luis David, Trujillo-Alonso Gersain, Calvo-Villalobos Ivan, Sanchez-Rangel Antonio, Ferrer-Alpuin Edgar, Ruiz-Jimenez Miguel, Corzo-Leon Dora E

机构信息

Hospital General "Dr. Miguel Silva" SSM, Morelia, Mexico.

Microbiology Gerency, Asesores Diagnóstico Clínico, Puebla, Mexico.

出版信息

Mycoses. 2022 Jan;65(1):65-70. doi: 10.1111/myc.13383. Epub 2021 Oct 28.

DOI:10.1111/myc.13383
PMID:34674319
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8662123/
Abstract

BACKGROUND

COVID-19-associated mucormycosis (CAM) has emerged as a challenging complication as the current pandemic has increased the population requiring treatment with corticosteroids. CAM has caused a massive outbreak in India, reported to be causing cases in Iran, Egypt and The Netherlands.

OBJECTIVES

To describe CAM cases occurring in a single centre in Western Mexico.

METHODS

Our group carried out a retrospective study from May 2020 to May 2021 to identify CAM cases in patients with previous COVID-19 diagnosis.

RESULTS

Six CAM cases occurred in a single centre in Western Mexico during the study period, most of them with diabetes (n = 5/6) and all received corticosteroid therapy even when only three had severe COVID-19. After analysing local COVID-19 burden, it was estimated that in this region, CAM was 300 times more frequent among COVID individuals than the estimates for general population.

CONCLUSION

Similar to large reports in India and other countries, CAM cases reported in this study were diagnosed in individuals with diabetes, hyperglycaemic status and with history of previous use of corticosteroids. Identifying these individuals at risk can help the early identification of CAM. In addition, strict glycaemic control and avoidance of unnecessary corticosteroid in non-severe COVID-19 cases could help in preventing this complicated fungal infection.

摘要

背景

随着当前疫情导致需要使用皮质类固醇进行治疗的人群增加,新型冠状病毒肺炎相关毛霉菌病(CAM)已成为一种具有挑战性的并发症。CAM在印度引发了大规模疫情,据报道在伊朗、埃及和荷兰也有病例出现。

目的

描述墨西哥西部一个单一中心发生的CAM病例。

方法

我们的团队在2020年5月至2021年5月期间进行了一项回顾性研究,以确定先前诊断为新型冠状病毒肺炎的患者中的CAM病例。

结果

在研究期间,墨西哥西部的一个单一中心出现了6例CAM病例,其中大多数患有糖尿病(n = 5/6),并且即使只有3例患有重症新型冠状病毒肺炎,所有患者均接受了皮质类固醇治疗。在分析当地新型冠状病毒肺炎负担后,据估计,在该地区,新型冠状病毒肺炎患者中CAM的发病率是普通人群估计发病率的300倍。

结论

与印度和其他国家的大型报告相似,本研究报告的CAM病例是在患有糖尿病、血糖升高且有先前使用皮质类固醇病史的个体中诊断出来的。识别这些高危个体有助于早期发现CAM。此外,在非重症新型冠状病毒肺炎病例中严格控制血糖并避免不必要的皮质类固醇使用可能有助于预防这种复杂的真菌感染。

相似文献

1
COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico.新型冠状病毒肺炎相关毛霉菌病、糖尿病与类固醇治疗:墨西哥西部单一中心的经验
Mycoses. 2022 Jan;65(1):65-70. doi: 10.1111/myc.13383. Epub 2021 Oct 28.
2
Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.COVID-19 相关毛霉病的流行病学、临床表现和治疗:来自印度西部浦那的单中心经验。
Mycoses. 2022 May;65(5):526-540. doi: 10.1111/myc.13435. Epub 2022 Mar 10.
3
Risk factors for COVID-19 associated mucormycosis in India: A case control study.印度 COVID-19 相关毛霉菌病的危险因素:一项病例对照研究。
Med Mycol. 2022 Jul 8;60(7). doi: 10.1093/mmy/myac044.
4
Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.冠状病毒病相关毛霉菌病(CAM):印度疫情期间的病例对照研究。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
5
COVID-19 associated mucormycosis - An emerging threat.新型冠状病毒肺炎相关毛霉菌病——一种新出现的威胁。
J Microbiol Immunol Infect. 2022 Apr;55(2):183-190. doi: 10.1016/j.jmii.2021.12.007. Epub 2022 Jan 13.
6
Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study.伊朗 COVID-19 相关毛霉菌病(CAM)患者的危险因素:一项单中心回顾性研究。
Mycopathologia. 2022 Dec;187(5-6):469-479. doi: 10.1007/s11046-022-00670-5. Epub 2022 Oct 6.
7
COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.新型冠状病毒肺炎相关鼻眶脑型毛霉菌病:伊朗一家三级医院的临床特征、抗真菌药敏性、治疗及转归
Mycopathologia. 2023 Oct;188(5):783-792. doi: 10.1007/s11046-023-00785-3. Epub 2023 Sep 6.
8
Mucormycosis and COVID-19: An epidemic within a pandemic in India.毛霉菌病与 COVID-19:印度大流行中的一场流行病。
Mycoses. 2021 Oct;64(10):1253-1260. doi: 10.1111/myc.13353. Epub 2021 Jul 24.
9
Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.印度冠状病毒疾病相关毛霉菌病的多中心流行病学研究。
Emerg Infect Dis. 2021 Sep;27(9):2349-2359. doi: 10.3201/eid2709.210934. Epub 2021 Jun 4.
10
Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review.毛霉菌病给新冠病毒患者带来额外负担:一项深入的系统评价。
J Infect Public Health. 2022 Nov;15(11):1299-1314. doi: 10.1016/j.jiph.2022.10.011. Epub 2022 Oct 14.

引用本文的文献

1
Epidemiology and prognostic factors of mucormycosis in France (2012-2022): a cross-sectional study nested in a prospective surveillance programme.法国毛霉病的流行病学及预后因素(2012 - 2022年):一项纳入前瞻性监测项目的横断面研究
Lancet Reg Health Eur. 2024 Aug 7;45:101010. doi: 10.1016/j.lanepe.2024.101010. eCollection 2024 Oct.
2
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.新冠病毒大流行后毛霉病的毒力特征和新型药物输送策略:全面综述。
Front Immunol. 2023 Sep 25;14:1264502. doi: 10.3389/fimmu.2023.1264502. eCollection 2023.
3
Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review.新型冠状病毒肺炎相关毛霉菌病(CAM)的临床表型:一项综述
Diagnostics (Basel). 2022 Dec 8;12(12):3092. doi: 10.3390/diagnostics12123092.
4
Father-Son COVID-19-associated mucormycosis: Important role of genetic susceptibility in combination with environmental factors.父子新冠病毒相关毛霉菌病:遗传易感性与环境因素相结合的重要作用。
Clin Case Rep. 2022 Sep 8;10(9):e6312. doi: 10.1002/ccr3.6312. eCollection 2022 Sep.
5
COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?新型冠状病毒肺炎相关真菌感染:是否迫切需要替代治疗方法?
Front Microbiol. 2022 Jun 9;13:919501. doi: 10.3389/fmicb.2022.919501. eCollection 2022.
6
Unnecessary Use of Corticosteroids for managing early mild symptoms of COVID-19 may lead to Rhino-ortibal-cerebral mucormycosis in Patients with Diabetes - a case series from Lahore, Pakistan.使用皮质类固醇治疗COVID-19早期轻度症状可能导致糖尿病患者发生鼻眶脑毛霉菌病——来自巴基斯坦拉合尔的病例系列
Ther Adv Infect Dis. 2022 May 6;9:20499361221097417. doi: 10.1177/20499361221097417. eCollection 2022 Jan-Dec.
7
First Molecular Identification of Three Clinical Isolates of Fungi Causing Mucormycosis in Honduras.洪都拉斯三株引起毛霉病的临床真菌分离株的首次分子鉴定
Infect Dis Rep. 2022 Apr 7;14(2):258-265. doi: 10.3390/idr14020031.
8
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.COVID-19 相关肺毛霉菌病的定义、诊断和管理:印度真菌感染研究论坛和肺病科学院的德尔菲共识声明。
Lancet Infect Dis. 2022 Sep;22(9):e240-e253. doi: 10.1016/S1473-3099(22)00124-4. Epub 2022 Apr 4.
9
In Silico Evaluation of Antifungal Compounds from Marine Sponges against COVID-19-Associated Mucormycosis.海洋海绵来源抗真菌化合物抗 COVID-19 相关毛霉病的计算机评估。
Mar Drugs. 2022 Mar 20;20(3):215. doi: 10.3390/md20030215.
10
Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis.COVID-19 相关毛霉菌病的临床特征和死亡率:系统评价和荟萃分析。
Mycopathologia. 2022 Jun;187(2-3):271-289. doi: 10.1007/s11046-022-00627-8. Epub 2022 Mar 21.

本文引用的文献

1
Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic.与 COVID-19 大流行期间毛霉菌病流行相关的危险因素。
Int J Infect Dis. 2021 Oct;111:267-270. doi: 10.1016/j.ijid.2021.08.037. Epub 2021 Aug 24.
2
COVID-19, corticosteroids and public health: a reappraisal.COVID-19、皮质类固醇和公共卫生:重新评估。
Public Health. 2021 Aug;197:48-55. doi: 10.1016/j.puhe.2021.05.028. Epub 2021 Jun 7.
3
Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study.在伊朗西部 COVID-19 大流行期间,一所教学治疗医院中鼻-眶-脑毛霉菌病发病率的增加:一项观察性研究。
Mycoses. 2021 Nov;64(11):1366-1377. doi: 10.1111/myc.13351. Epub 2021 Jul 31.
4
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.印度 2826 例 COVID-19 相关的鼻-眶-脑毛霉菌病的流行病学、临床特征、治疗和结局 - 合作 OPAI-IJO 新冠病毒相关毛霉菌病研究(COSMIC),报告 1。
Indian J Ophthalmol. 2021 Jul;69(7):1670-1692. doi: 10.4103/ijo.IJO_1565_21.
5
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.ECMM/ISHAM 关于中低收入国家 COVID-19 相关毛霉菌病临床管理的建议。
Mycoses. 2021 Sep;64(9):1028-1037. doi: 10.1111/myc.13335. Epub 2021 Jul 26.
6
Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间,一家三级医疗中心收治的鼻眶脑毛霉菌病病例激增。
Front Med (Lausanne). 2021 May 28;8:645270. doi: 10.3389/fmed.2021.645270. eCollection 2021.
7
Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021.荷兰 2020 年 12 月至 2021 年 5 月期间 4 例 COVID-19 患者继发毛霉菌病的病例系列。
Euro Surveill. 2021 Jun;26(23). doi: 10.2807/1560-7917.ES.2021.26.23.2100510.
8
SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.SARS-CoV-2 感染人类胰腺 β 细胞并引起 β 细胞损伤。
Cell Metab. 2021 Aug 3;33(8):1565-1576.e5. doi: 10.1016/j.cmet.2021.05.013. Epub 2021 May 18.
9
The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.伴侣蛋白 GRP78 是 SARS-CoV-2 的宿主辅助因子,GRP78 耗尽抗体可阻断病毒进入和感染。
J Biol Chem. 2021 Jan-Jun;296:100759. doi: 10.1016/j.jbc.2021.100759. Epub 2021 May 7.
10
Host-Pathogen Molecular Factors Contribute to the Pathogenesis of spp. in Diabetes Mellitus.宿主-病原体分子因素促成糖尿病中 spp. 的发病机制。
Curr Trop Med Rep. 2021;8(1):6-17. doi: 10.1007/s40475-020-00222-1. Epub 2021 Jan 22.